This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA).
KEI-Risdiplan-patent-license-request-8july2022
This was the August 5, 2022 response from Roche.
Roche-Response-to-Risdiplam-license-request–5Aug2022
KEI wrote to Roche again on February 23, 2024, regarding efforts to manufacture generic risdiplam in South Africa.
KEI2Thomas-Winkler-23Feb2024-risdiplam-SouthAfrica
KEI wrote to Roche on February 26, 2024, asking for a voluntary license to manufacture generic risdiplam in South Africa.
KEI2Thomas-Winkler-26Feb2024-Roche- SouthAfrica-risdiplam
Roche wrote to KEI on March 19, 2024, rejecting the South Africa license request.
Thomas-Winkler2KEI-19March2024-risdiplam-SouthAfrica
KEI wrote to Roche on May 2, 2024, asking for a meeting at Roche Headquarters to discuss a voluntary license.
KEI2Thomas-Winkler-2May2024
Roche wrote to KEI on May 17, 2024, declining the meeting request.
Thomas-Winkler2KEI-17May2024-risdiplam